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Abstract
Background
Atherosclerotic cardiovascular disease (ASCVD) is driven by multifaceted contributions of
the immune system. However, the dysregulation of immune cells that leads to ASCVD is
poorly understood. We determined the association of components of innate and adaptive
immunity longitudinally with ASCVD, and assessed whether arterial calcifications play a role
in this association.
Methods and findings
Granulocyte (innate immunity) and lymphocyte (adaptive immunity) counts were determined
3 times (2002–2008, mean age 65.2 years; 2009–2013, mean age 69.0 years; and 2014–
2015, mean age 78.5 years) in participants of the population-based Rotterdam Study with-
out ASCVD at baseline. Participants were followed-up for ASCVD or death until 1 January
2015. A random sample of 2,366 underwent computed tomography at baseline to quantify
arterial calcification volume in 4 vessel beds. We studied the association between immunity
components with risk of ASCVD and assessed whether immunity components were related
to arterial calcifications at baseline. Of 7,730 participants (59.4% women), 801 developed
ASCVD during a median follow-up of 8.1 years. Having an increased granulocyte count
increased ASCVD risk (adjusted hazard ratio for doubled granulocyte count [95% CI] = 1.78
[1.34–2.37], P < 0.001). Higher granulocyte counts were related to larger calcification vol-
umes in all vessels, most prominently in the coronary arteries (mean difference in calcium
volume [mm3] per SD increase in granulocyte count [95% CI] = 32.3 [9.9–54.7], P < 0.001).
Respectively, the association between granulocyte count and incident coronary heart dis-
ease and stroke was partly mediated by coronary artery calcification (overall proportion
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mediated [95% CI] = 19.0% [−10% to 32.3%], P = 0.08) and intracranial artery calcification
(14.9% [−10.9% to 19.1%], P = 0.05). A limitation of our study is that studying the etiology of
ASCVD remains difficult within an epidemiological setting due to the limited availability of
surrogates for innate and especially adaptive immunity.
Conclusions
In this study, we found that an increased granulocyte count was associated with a higher
risk of ASCVD in the general population. Moreover, higher levels of granulocytes were asso-
ciated with larger volumes of arterial calcification. Arterial calcifications may explain a pro-
portion of the link between granulocytes and ASCVD.
Author summary
Why was this study done?
• Many people develop cardiovascular disease during their lifetime.
• Recent findings suggest a role of the immune system in the pathogenesis of cardiovascu-
lar disease.
• Currently, there is no low-cost treatment identified to treat dysregulations of the
immune system for preventing cardiovascular disease, because the exact immune cells
involved in cardiovascular pathology are unknown.
What did the researchers do and find?
• We repeatedly quantified the number of innate immune cells (granulocytes and plate-
lets) and adaptive immune cells (lymphocytes) from 7,730 people who participated in
the Dutch population-based Rotterdam Study and determined the relation of these cells
with the risk of cardiovascular disease.
• The risk of cardiovascular disease was higher among people with increased granulocytes
over time, while the risk was lower among people with increased lymphocytes.
What do these findings mean?
• The findings suggest that higher activity of the innate immune system and lower activity
of the adaptive immune system may be associated with higher risk of cardiovascular
disease.
• The relation between granulocytes and the risk of cardiovascular disease may be medi-
ated by subclinical atherosclerosis.
• The findings warrant future studies that could focus more specifically on targeting both
innate and adaptive immunity, rather than only innate immunity, and refine insights
into these pathways.
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Introduction
Atherosclerotic cardiovascular disease (ASCVD) arises from various interacting pathophysio-
logical processes [1]. Recent findings point towards a key role of the immune system, which
can be broadly classified into innate and adaptive immunity [2]. Innate immunity refers to
immune responses present at birth, whereas adaptive immunity is acquired during life by
exposure to antigens [3]. The role of innate immunity in the pathophysiology of ASCVD has
been recognized on the basis of evidence from experimental and observational data [4–8]. To
date, however, no easy, accessible, low-cost treatment has been identified to effectively target
the innate immune system for preventing ASCVD [8]. Given the mechanistic diversity of
inflammatory pathways, considering other pathways could widen avenues for therapeutic tar-
gets, for example targeting the adaptive immune system. Adaptive immune cells may provide
protective responses at atherosclerotic sites, as has been shown in neurodegenerative disorders
[9,10] and also in cardiovascular disease in experimental and clinical studies [11]. Moreover,
repeatedly measuring inflammation may better capture the biologically dynamic processes of
these 2 immune systems than a single measurement, because of the assessment of changes over
time.
Recent work from the field of cancer research suggests that measuring granulocytes and
platelets provides important markers of innate immunity [12–14], whereas measuring lym-
phocytes yields information on adaptive immunity [15]. Furthermore, combining these mea-
surements into ratios, i.e., the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte
ratio (PLR), and systemic immune-inflammation index (SII), is thought to even better reflect
the relative balance between innate and adaptive immunity [16–18]. In this study, we first
determined the longitudinal association of these immunity components with risk of ASCVD
in the general population by using the framework of joint models for longitudinal and survival
data, and hypothesized that an increase in innate immunity markers and decrease in adaptive
immunity lead to increased risk of ASCVD. Second, we examined the association between the
immunity components and arterial calcifications to explore atherosclerosis as a possible
mediator.
Methods
Study population
The present study is embedded within the Rotterdam Study, a prospective population-based
cohort study in Rotterdam, the Netherlands. The Rotterdam Study started in 1989 with 7,983
persons (78% response rate) aged�55 years and residing in the district Ommoord, a suburb
of Rotterdam. This first subcohort (RS-I) was extended with a second subcohort (RS-II) in
2000, consisting of 3,011 persons (67% response rate) aged�55 years, and with a third subco-
hort (RS-III) in 2006, composed of 3,932 persons aged�45 years (65% response rate). The
design of the Rotterdam Study has been described in detail previously [19]. In brief, partici-
pants were examined at study entry and at follow-up visits every 3 to 5 years. They were inter-
viewed at home by a trained research nurse, followed by 2 visits at the research facility for
additional interviewing, laboratory assessments, and imaging.
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus
MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and
Sport (Population Screening Act [WBO], license number 1071272-159521-PG). The Rotter-
dam Study personal registration data collection is filed with the Erasmus MC Data Protection
Officer under registration number EMC1712001. The Rotterdam Study has been entered into
the Netherlands Trial Register (https://www.trialregister.nl) and into the WHO International
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Clinical Trials Registry Platform (https://www.who.int/ictrp/network/primary/en/) under the
shared catalogue number NTR6831. All participants provided written informed consent to
participate in the study and to have their information obtained from treating physicians.
For the current study, the analysis plan was drafted in January 2019 (S1 Analysis Plan). This
study is reported as per the Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE) guideline (S1 STROBE Checklist).
Laboratory tests for granulocytes, platelets, and lymphocytes were introduced from 2002
onwards, corresponding with the following assessment rounds in the Rotterdam Study (base-
line in this study): fourth round of RS-I, second round of RS-II, and first round of RS-III
(n = 9,996 in total).
Assessment of blood cell counts and their derived ratios
Fasting blood samples were drawn during each visit at the research center, with a maximum
of 3 visits during follow-up. From 7,730 participants, 5,085 participants were available for a
second blood cell assessment, and 270 participants were available for a third blood cell assess-
ment. Full blood count measurements were performed using the Coulter AcT diff2 Hematol-
ogy Analyzer (Beckman Coulter, Brea, CA, US) directly after the blood sample was drawn.
Laboratory measurements included absolute granulocyte, platelet, and lymphocyte counts in
109 per liter. GLR and PLR were calculated as the ratio of granulocyte count to lymphocyte
count and as the ratio of platelet count to lymphocyte count, respectively. SII was defined as
platelet count times GLR [20].
Assessment of stroke and coronary heart disease
The clinical outcomes of interest included first fatal or nonfatal stroke or coronary heart dis-
ease (CHD) separately as well as combined into ASCVD as previously described. Follow-up
data were collected through general practitioners and subsequent collection of information
from letters by medical specialists and discharge reports, in cases of hospitalization. CHD
included (1) nonfatal myocardial infarction (MI) and (2) CHD mortality (mortality with defi-
nite MI, definite CHD, or possible CHD as underlying cause of death) [21]. Stroke was defined
as a syndrome of rapidly developing symptoms of focal or global cerebral dysfunction lasting
�24 hours or leading to death, with apparent vascular cause [22,23]. We categorized strokes as
ischemic or hemorrhagic, based on neuroimaging reports and clinical symptoms, or as
unspecified if we were unable to differentiate the stroke type further. Subarachnoid hemor-
rhages due to ruptured aneurysms were not considered as stroke. Follow-up was virtually com-
plete until 1 January 2015 (96.6% of potential person-years observed). ASCVD furthermore
included other ASCVD mortality.
Assessment of arterial calcification
Non-contrast computed tomography (CT) images were obtained using a 16-slice or 64-slice
multidetector CT scanner (Somatom Sensation 16 or 64; Siemens, Forchheim, Germany).
Using a cardiac scan and an extracardiac scan that reached from the aortic root to the intracra-
nial vasculature (1 centimeter above the sella turcica), we visualized the following vessels: coro-
nary arteries, aortic arch, extracranial internal carotid arteries, and intracranial internal
carotid arteries. Radiation dose and other imaging parameters of both scans are described else-
where [24,25].
The amount of calcification in the coronary arteries, aortic arch, and extracranial carotid
arteries was quantified using widely used, commercially available dedicated software (Syngo.
via; Siemens). Calcification in the coronary arteries comprised a summation of calcification in
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the left main, left anterior descending, left circumflex, and right coronary artery. Calcification
in the aortic arch was scored from the origin of the aortic arch (defined as the image in which
the ascending and descending aorta merge into the inner curvature of the aortic arch) to the
first 1 cm of the branches originating from the arch. Calcification in the extracranial carotid
arteries was assessed within 3 cm proximal and distal of the bifurcation on both sides and
summed.
Intracranial internal carotid artery calcification was assessed from the horizontal segment
of the petrous internal carotid artery to the top of the internal carotid artery. Scoring was done
semi-automatically, because automated software is not yet available for this region (the close
relationship between calcification and the skull base precludes the use of commercial software
given a high false-positive rate). Regions of interest were manually drawn in the course of the
intracranial internal carotid artery on both sides, after which the number of pixels within these
regions above 130 Hounsfield units was summed and multiplied by the pixel size and the slice
increment in order to obtain a volume in cubic millimeters [26,27].
Covariates
We assessed education, smoking, and use of antihypertensive, lipid-lowering, and antidiabetic
medication at baseline by interview. Diastolic and systolic blood pressures were measured
twice on the right arm with a random-zero sphygmomanometer, of which the mean was used.
Total cholesterol and high-density lipoprotein (HDL) cholesterol were measured with a Coul-
ter AcT diff2 Hematology Analyzer. Body mass index (BMI) was computed from measure-
ments of height and weight (kg/m2). Diabetes mellitus was defined as use of antidiabetic
medication, fasting serum glucose level� 7.1 mmol/l (�127.9 mg/dl), or random non-fasting
serum glucose level� 11.1 mmol/l (�200.0 mg/dl) [28]. High-sensitivity C-reactive protein
(hs-CRP) was determined in serum that was drawn during the third assessment round in the
Rotterdam Study, i.e., third round of RS-I (1996–1999), which was stored at −20˚C until per-
formance of the hs-CRP measurements in 2003 to 2004. hs-CRP was measured using Rate
Near Infrared Particle Immunoassay (Immage Immunochemistry System, Beckman Coulter).
History of cancer was obtained from general practitioners’ medical records (including hospital
discharge letters), the Dutch Hospital Data registry, and regional histopathology and cytopa-
thology registries. Furthermore, we assessed history of immune-modulating medication use—
nonsteroidal anti-inflammatory drugs (NSAIDs) (ATC code M01), immunosuppressives
(ATC code L04), and methotrexate (ATC code L01BA01)—by number of prescriptions
between 1 January 1995 and blood draw date.
Statistical analysis
Because the blood cell counts and their derived ratios have a skewed distribution and to adhere
to the linearity assumptions, the analysis was based on the natural logarithmic (Ln) transfor-
mation of their values. We first determined the association of the granulocyte, platelet, and
lymphocyte counts and their derived ratios with the risk of stroke and CHD separately as well
as ASCVD, using the framework of joint models for longitudinal and survival data [29]. For
the longitudinal data, a linear mixed effects model was used, in which we specified the immu-
nity component as the dependent variable and time as the independent variable to assess the
mean change in immunity components. Random intercepts and slopes were used to incorpo-
rate individual response trajectories. For modeling survival data, we used a Cox regression
model in which we included the true underlying profile of the blood cell counts as estimated
from the longitudinal model. Here the baseline risk function assumed a piecewise constant
with 6 knots placed at equally spaced percentiles of the observed event times. Joint models
PLOS MEDICINE Immune system and risk of cardiovascular disease
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allow accounting for (1) measurement error during follow-up, i.e., biological variation, (2) the
effect of factors at an earlier time point on the values of blood cell measurements at a later time
point [30], and (3) the correlations in the repeated measurements of the blood cell counts.
Because we are using log-log models (logYi = α + βlogXi + ε), we report hazard ratios (HRs)
with 95% confidence intervals (CIs) obtained by exponentiating Ln(2) times the estimated
coefficients from the Cox model. These HRs correspond to the increase in risk for a doubling
of the blood cell count or ratio. We computed 2 nested models: Model I was adjusted for base-
line age (continuous, centered as age minus mean age) and sex; model II was additionally
adjusted for education, smoking status, BMI, diabetes mellitus, systolic and diastolic blood
pressure (continuous, centered as blood pressure minus mean blood pressure), antihyperten-
sive medication, total cholesterol, HDL cholesterol, and lipid-lowering medication. For assess-
ment of the association between individual blood cell counts and ASCVD, we performed the
analyses with adjustment for the baseline blood cell counts of the remaining 2 blood cell types.
Follow-up time was used as the time scale and started at the date of first laboratory assessment;
follow-up continued until date of stroke, CHD, death, loss to follow-up, or 1 January 2015,
whichever came first. We also investigated the association of the blood cell counts and their
ratios with ischemic and hemorrhagic stroke separately. We assessed the joint model assump-
tions by examining the proportional hazards assumption using Schoenfeld residuals, and
goodness of fit using Cox–Snell residuals for the survival part and marginal residuals for the
longitudinal part.
In sensitivity analyses, we additionally excluded participants with a history of cancer or a
history of immune-modulating medication at baseline. In addition, we performed additional
adjustments for NSAID use. We explored effect modification by stratifying by age, sex, hs-
CRP (at a cutoff of 2 mg/l), use of lipid-lowering medication, coronary artery calcification vol-
ume (at a cutoff of 10 mm3), and smoking, all at baseline. We formally tested interaction
between these factors and blood cell counts on the multiplicative scale by adding interaction
terms to model II. Lastly, we repeated the analyses for the granulocytes and lymphocytes and
risk of ASCVD using age as the time scale instead of follow-up time to account for potential
residual confounding by age and to minimize potential effects of left truncation.
Next, in order to explore possible mechanisms, we performed a cross-sectional analysis
assessing the association of the granulocyte, platelet, and lymphocyte counts and their derived
ratios at baseline, per standard deviation increase, with calcification volume in each vessel bed
(coronary arteries, aortic arch, extracranial carotid arteries, and intracranial carotid arteries)
using linear regression models. To facilitate interpretation of these analyses, we chose to first
standardize the blood cell counts only, to make results comparable, and keep the rest of the
variables untransformed. We adjusted these analyses for age and sex (model I), and addition-
ally for education, smoking status, BMI, diabetes mellitus, systolic blood pressure, diastolic
blood pressure, antihypertensive medication, total cholesterol, HDL cholesterol, and lipid-low-
ering medication (model II). To adhere to the homoscedasticity and linearity assumptions, we
repeated linear regression models after natural log-transforming exposure and outcome vari-
ables. As a sensitivity analysis, we looked at the association between the granulocyte, platelet,
and lymphocyte counts and their derived ratios and continuous arterial calcification only in
those with non-zero arterial calcification, since the magnitude of the increase from 0 to 1 for
volume may not be the same as other incremental increases in arterial calcification.
Finally, we performed a mediation analysis to assess a possible mediating effect of calcifica-
tion volume in the coronary arteries and intracranial carotid arteries on the association
between innate immunity and the risk of CHD and stroke, respectively. We chose the innate
immunity marker displaying the strongest association with both calcifications and incident
CHD or stroke for this analysis. We tested the overall proportion mediated by calcifications.
PLOS MEDICINE Immune system and risk of cardiovascular disease
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To test for mediation effects, we used the decomposition analysis techniques as described by
VanderWeele [31]. Participants with a history of CHD or stroke were excluded from the analy-
sis. We analyzed the association of innate immunity with calcifications with linear regression
models. The association of innate immunity or calcifications with CHD or stroke was investi-
gated by Cox regression models.
Multiple imputation by chained equations was used for missing covariates (maximum of
1.5%), with 5 imputed datasets based on other covariates and the outcome. Rubin’s method
was used for pooling the 5 analyses to obtain pooled HRs and 95% CIs [32]. Two-sided
P< 0.05 was considered statistically significant for all analyses. Statistical analyses were per-
formed using the R packages mice, survival, nlme, JM, and JMbayes in RStudio Version 3.3.2
[29,30,33,34].
Results
From 8,712 participants, we excluded those with a history of ASCVD (n = 819) at baseline,
those who had incomplete data regarding their history of ASCVD (n = 95), and those who did
not provide informed consent to assess medical records during follow-up (n = 60). Lastly, we
excluded participants with incomplete laboratory assessment (n = 8), resulting in 7,730 partici-
pants for analysis (flowchart in Fig 1). From the fourth round of RS-I and the second round of
RS-II, a random sample was invited to undergo non-contrast CT to quantify arterial calcifica-
tion. Of these participants, 2,366 had complete calcification and blood assessment.
Characteristics of the study participants are presented in Table 1. Mean age of included
study participants was 65.2 years, and 59.4% were women. During a median (interquartile
range) follow-up of 8.1 (3.4) years (62,095 person-years), 801 participants developed ASCVD,
of whom 423 participants developed CHD and 378 stroke. ASCVD-free survival probability
and average change of granulocytes and lymphocytes over time are presented in S1 Fig in the
total population and in S2 Fig in younger and older individuals separately.
An increased granulocyte count, but not platelet count, was associated with an increased
risk of ASCVD (adjusted HR [95% CI] for doubled granulocyte count = 1.78 [1.34–2.37], P<
0.001, and for doubled platelet count = 1.17 [0.90–1.51], P = 0.24, Table 2). With respect to
Fig 1. Flowchart of study population. ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease.
https://doi.org/10.1371/journal.pmed.1003115.g001
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adaptive immunity, an increased level of lymphocytes was associated with a decreased risk of
ASCVD, although this result was not statistically significant (adjusted HR for doubled lympho-
cyte count [95% CI] = 0.87 [0.71–1.06], P = 0.17). Both an increased GLR and an increased SII
were associated with increased ASCVD risk (adjusted HR for doubled GLR [95% CI] = 1. 37
[1.14–1.65], P = 0.001, and for doubled SII = 1.19 [1.03–1.36], P = 0.02), whereas an increased
PLR was not associated with ASCVD risk. We observed no major violations of the joint model
assumptions. Effect estimates did not materially change, and in fact became stronger, when we
excluded participants with a history of cancer or history of immune-modulating medication at
baseline (723 ASCVD cases among 7,063 remaining participants) (adjusted HR for doubled
granulocyte count [95% CI] = 1.90 [1.41–2.57], P< 0.001, and for doubled lymphocyte
count = 0.82 [0.65–1.04], P = 0.10). Additional adjustment for NSAID use did not change the
effect estimates. We found that the association between higher levels of granulocytes and risk
of ASCVD was more pronounced in participants aged younger than the median age of 64
Table 1. Baseline characteristics.
Characteristic Laboratory assessment cohort
N = 7,730
Sample undergoing CT
N = 2,366
Women 4,594 (59.4%) 1,236 (52.2%)
Age, years 65.2 (10.2) 69.1 (6.7)
Smoking
Ever 5,278 (68.7%) 1,662 (71.2%)
Never 2,401 (31.3%) 670 (28.7%)
Diabetes mellitus 415 (5.4%) 129 (5.5%)
BMI, kg/m2 27.6 (4.4) 27.6 (4.0)
Education
Primary 830 (10.8%) 179 (7.7%)
Lower 3,124 (40.7%) 979 (42.1%)
Intermediate 2,205 (28.8%) 716 (30.8%)
Higher 1,509 (19.7%) 451 (19.4%)
Systolic blood pressure, mm Hg 142.3 (21.8) 146.7 (20.0)
Diastolic blood pressure, mm Hg 81.3 (11.0) 80.2 (10.7)
Antihypertensive drugs 2,571 (33.6%) 921 (39.5%)
Total cholesterol, mmol/l 5.7 (1.0) 5.6 (1.0)
HDL cholesterol, mmol/l 1.5 (0.4) 1.4 (0.4)
Lipid-lowering medication 1,429 (18.7%) 535 (23.0%)
Granulocyte count, ×103/μl 4.0 (1.4) 4.0 (1.3)
Platelet count, ×103/μl 270.9 (66.6) 259.0 (64.0)
Lymphocyte count, ×103/μl 2.3 (1.1) 2.3 (1.0)
GLR 1.9 (0.8) 1.9 (0.9)
PLR 127.9 (46.4) 124.9 (45.8)
SII 509.3 (270.7) 494.3 (272.2)
Data presented as mean (standard deviation) for continuous variables and number (percentage) for categorical variables. Number of missing values for the ASCVD-free
cohort: 51 (0.7%) for smoking, 22 (0.3%) for diabetes, 25 (0.3%) for BMI, 62 (0.8%) for education, 41 for systolic and diastolic blood pressure (0.5%), 69 for blood
pressure lowering medication (0.9%), 25 for cholesterol (0.3%), 27 for HDL cholesterol (0.3%), and 69 for lipid lowering medication (0.9%). Number of missing values
for the sample undergoing CT are: 52 (0.6%) for smoking, 22 (0.3%) for diabetes, 26 (0.3%) for BMI, 41 (0.5%) for education, 14 for systolic and diastolic blood pressure
(0.6%), 35 for blood pressure lowering medication (1.5%), 6 for cholesterol (0.3%), 6 for HDL cholesterol (0.3%) and 35 for lipid lowering medication (1.5%).
BMI, body mass index; CT, computed tomography; GLR, granulocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation
index.
https://doi.org/10.1371/journal.pmed.1003115.t001
PLOS MEDICINE Immune system and risk of cardiovascular disease
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003115 May 7, 2020 8 / 16
years compared to those 64 years or older (adjusted HR for doubled granulocyte count [95%
CI] = 2.32 [1.20–4.47], P< 0.001) (Pinteraction = 0.002). Results of all stratified analyses with
interaction terms are shown in S1 Table. Lastly, risk estimates were comparable when using
age as the time scale instead of follow-up time.
When examining CHD and stroke as separate events, an increased granulocyte count was
associated with an increased risk of both events (adjusted HR for doubled granulocyte count
[95% CI] = 1.98 [1.34–2.93], P = 0.001, for CHD and 1.50 [1.00–2.27], P = 0.05, for stroke;
Table 2). An increased platelet count was associated with higher risk of stroke only (adjusted
HR for doubled platelet count [95% CI] = 1.38 [0.95–2.01], P = 0.09). An increased lymphocyte
count showed similar protective effects for both CHD and stroke, although these effects were
not statistically significant (adjusted HR for doubled lymphocyte count [95% CI] = 0.88 [0.66–
1.17], P = 0.37, for CHD and 0.85 [0.63–1.15], P = 0.29, for stroke). With respect to the ratio
measures, an increased GLR was associated with both increased CHD and stroke risk (adjusted
HR for doubled GLR [95% CI] = 1.37 [1.07–1.78], P = 0.01, for CHD and 1.31 [1.00–1.70], P =
0.05, for stroke). When investigating ischemic and hemorrhagic stroke separately, an increased
granulocyte count was associated with an increased risk of ischemic stroke (HR for doubled
Table 2. Joint models for the association between repeated blood-based immunity markers and subsequent risk of ASCVD.
Model and immunity marker ASCVD
n/N = 801/7,730
Stroke
n/N = 378/7,730
CHD
n/N = 423/7,730
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Model I
Innate immunity�
Granulocytes 2.63 (2.03–3.40) <0.001 2.14 (1.48–3.11) <0.001 3.10 (2.18–4.42) <0.001
Platelets 1.10 (0.85–1.41) 0.47 1.27 (0.88–1.83) 0.21 0.96 (0.68–1.36) 0.83
Adaptive immunity�
Lymphocytes 1.03 (0.85–1.25) 0.77 0.96 (0.72–1.29) 0.80 1.09 (0.83–1.43) 0.54
Balance between innate and adaptive immunity
GLR 1.52 (1.27–1.82) <0.001 1.47 (1.13–1.91) 0.004 1.56 (1.22–2.01) <0.001
PLR 1.02 (0.87–1.19) 0.84 1.15 (0.91–1.46) 0.24 0.97 (0.78–1.20) 0.76
SII 1.25 (1.09–1.43) 0.002 1.27 (1.04–1.56) 0.02 1.24 (1.03–1.51) 0.03
Model II
Innate immunity�
Granulocytes 1.78 (1.34–2.37) <0.001 1.50 (1.00–2.27) 0.05 1.98 (1.34–2.93) 0.001
Platelets 1.17 (0.90–1.51) 0.24 1.38 (0.95–2.01) 0.09 1.01 (0.71–1.44) 0.95
Adaptive immunity�
Lymphocytes 0.87 (0.71–1.06) 0.17 0.85 (0.63–1.15) 0.29 0.88 (0.66–1.17) 0.37
Balance between innate and adaptive immunity
GLR 1.37 (1.14–1.65) 0.001 1.31 (1.00–1.70) 0.05 1.37 (1.07–1.78) 0.01
PLR 1.17 (0.99–1.38) 0.06 1.25 (0.98–1.59) 0.07 1.10 (0.88–1.38) 0.41
SII 1.19 (1.03–1.36) 0.02 1.21 (0.99–1.48) 0.06 1.16 (0.96–1.41) 0.13
HR is per doubled blood cell count. Model I is adjusted for age and sex. Model II is adjusted for age, sex, education, smoking status, body mass index, diabetes mellitus,
systolic and diastolic blood pressure, antihypertensive medication, high-density lipoprotein cholesterol, total cholesterol, and lipid-lowering medication. All markers
were logarithmically transformed.
�Analysis for each blood cell type adjusted for the baseline blood cell counts of the remaining 2 blood cell types.
ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CI, confidence interval; GLR, granulocyte-to-lymphocyte ratio; HR, hazard ratio; n,
number of incident events; N, number of participants for analysis; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index (defined as platelet
count times GLR).
https://doi.org/10.1371/journal.pmed.1003115.t002
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granulocyte count [95% CI] = 1.44 [0.90–2.31], P = 0.13) and hemorrhagic stroke (2.48 [0.86–
7.14], P = 0.09), whereas platelets only increased risk of ischemic stroke (HR for doubled plate-
let count [95% CI] = 1.44 [0.93–2.22], P = 0.10).
Regarding the association of immunity with arterial calcification, we found that higher lev-
els of granulocytes at baseline related to larger calcification volumes in all arteries, but most
prominently in the coronary arteries (mean difference in calcium volume [mm3] per SD
increase in granulocyte count [95% CI] = 32.3 [9.1 to 54.7], P< 0.001). Regarding adaptive
immunity, higher levels of lymphocytes were not related to calcification volumes. Higher levels
of GLR and SII were related to larger calcification volumes in the aortic arch only (mean differ-
ence in calcium volume [mm3] per SD increase [95% CI] = 48.6 [2.5 to 94.8], P = 0.04, and
58.8 [13.8 to103.8], P = 0.03, respectively). In Table 3, the linear regression models after trans-
forming the exposure and outcome variables are presented. Our sensitivity analyses with non-
zero calcifications similarly showed associations between higher levels of granulocytes and
larger calcification volumes in all arteries, but the analysis with extracranial internal carotid
artery calcification as outcome did not reach statistical significance.
The association between granulocytes and incident CHD was partly mediated by coronary
artery calcifications (overall proportion mediated [95% CI] = 19.0% [−10% to 32.3%], P =
0.08), while the association between granulocytes and incident stroke was partly mediated by
intracranial artery calcifications (14.9% [−10.9% to 19.1%], P = 0.05), albeit this finding was
not statistically significant.
Discussion
In this study, we found that an increase of innate immunity markers over time, as reflected by
a doubling of the granulocyte count and the ratios GLR and SII, was robustly associated with a
higher risk of ASCVD. Furthermore, higher levels of granulocytes at baseline were related to
larger burden of subclinical atherosclerosis, as measured by arterial calcifications. Coronary
Table 3. Models for the association between blood-based immunity markers and arterial calcification volume.
Immunity markera Arterial calcification volumeb
Coronary arteries Aortic arch Extracranial internal carotid Intracranial internal carotid
Mean difference
(95% CI)
P value Mean difference
(95% CI)
P value Mean difference
(95% CI)
P value Mean difference
(95% CI)
P value
Innate immunity�
Granulocytes 0.26 (0.14; 0.39) <0.001 0.20 (0.07; 0.32) <0.001 0.22 (0.09; 0.35) <0.001 0.18 (0.05; 0.32) 0.01
Platelets −0.02 (−0.18; 0.13) 0.76 0.01 (−0.14; 0.17) 0.87 −0.05 (−0.21; 0.11) 0.57 −0.09 (−0.25; 0.07) 0.27
Adaptive immunity�
Lymphocytes 0.15 (0.03; 0.27) 0.02 0.01 (−0.11; 0.13) 0.91 0.09 (−0.04; 0.21) 0.17 0.08 (−0.04; 0.21) 0.19
Balance between innate and adaptive immunity
GLR 0.06 (−0.04; 0.15) 0.24 0.10 (0.00; 0.19) 0.04 0.06 (−0.03; 0.16) 0.18 0.04 (−0.05; 0.14) 0.36
PLR −0.09 (−0.19; 0.01) 0.08 0.01 (−0.09; 0.11) 0.85 −0.06 (−0.17; 0.04) 0.25 −0.08 (−0.18; 0.03) 0.15
SII 0.06 (−0.01; 0.14) 0.10 0.09 (0.01; 0.16) 0.03 0.06 (−0.02; 0.13) 0.15 0.03 (−0.05; 0.11) 0.48
Adjusted for age, sex, education, smoking status, body mass index, diabetes mellitus, systolic and diastolic blood pressure, antihypertensive medication, high-density
lipoprotein cholesterol, total cholesterol, and lipid-lowering medication.
aAll markers were natural log-transformed (Ln[immunity component × 103/μl]).
bWe added 1.0 mm3 to the non-transformed values to deal with calcification volumes of 0 and used standardized natural log-transformed values (Ln[calcification
volume + 1.0 mm3]).
�Analysis for each blood cell type adjusted for the baseline blood cell counts of the remaining 2 blood cell types.
CI, confidence interval; GLR, granulocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.
https://doi.org/10.1371/journal.pmed.1003115.t003
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artery calcifications mediated 19.0% of the association between granulocytes and CHD, while
intracranial artery calcifications mediated 14.9% of the association between granulocytes and
stroke.
To date, few population-based studies have investigated the association between innate
immunity markers and cardiovascular outcomes. Elevated GLR has been linked to ischemic
stroke incidence and cardiovascular disease [35,36]. A meta-analysis of 38 studies showed that
elevated GLR was associated with coronary artery disease, acute coronary syndrome, stroke,
and composite cardiovascular events [37]. However, most of these studies were cross-sectional
or were performed in selected clinical populations of patients with cardiovascular disease.
Besides observational studies, various clinical trials have targeted the immune system to reduce
the risk of ASCVD. One of the largest is the CANTOS (Canakinumab Anti-inflammatory
Thrombosis Outcome Study) randomized trial, in which patients with elevated hs-CRP and
previous MI were assigned to receive canakinumab or placebo. Canakinumab selectively
inhibits interleukin-1β, resulting in an inhibition of the innate immunity. The 150-mg dose
resulted in a lower incidence of recurrent cardiovascular events, compared to placebo [38]. In
addition to interleukin-1β, also hs-CRP, fibrinogen, and interleukin-6, all markers in the same
cascade, have been shown to have an association with CHD [39–41]. Our findings also show
an important role of innate immunity in first-ever stroke and CHD risk in the general popula-
tion, independent of hs-CRP level or lipid-lowering medication use.
Interestingly, a more recent trial assessing low-dose methotrexate to reduce inflammation
in order to prevent recurrent cardiovascular disease showed that methotrexate did not lower
levels of interleukin-1β, interleukin-6, or hs-CRP, and that it did not result in a lower number
of cardiovascular events compared to placebo [8]. Together with the results from the CANTOS
trial, these studies indicate that reducing the risk of cardiovascular events through inflamma-
tion may depend on the pathway targeted. In addition to these established pathways, our
results indicate that the pathway of adaptive immunity may also affect the risk of cardiovascu-
lar disease. More specifically, lymphocyte count, an important player in adaptive immunity,
showed protective effects on the risk of ASCVD, although this finding was not statistically sig-
nificant. Indeed, mobilizing anti-inflammatory T cells to atherosclerotic sites may provide pro-
tective responses as has been shown in neurodegenerative disorders [9] and also in
cardiovascular disease in experimental and clinical studies [11]. These cells thus additionally
serve as a promising therapeutic target to control the proinflammatory processes of atheroscle-
rosis. The significant association we found between GLR and SII and incident ASCVD,
although weaker than with granulocytes, supports the hypothesis that ASCVD results from an
imbalance between innate and adaptive immunity. Future studies may focus more specifically
on targeting both innate and adaptive immunity, rather than only innate immunity, and refine
insights into these pathways.
Although previous studies have established the inflammatory hypothesis of atherothrombo-
sis in coronary artery disease, fewer studies have specifically investigated stroke. However,
increasing evidence from experimental studies suggests an equally important role for the
immune response in stroke [42]. Similarly, we demonstrated that higher levels of granulocytes
were associated with stroke of any type, as well as with ischemic and hemorrhagic stroke sepa-
rately. Especially the latter finding warrants further research since most studies so far have
mainly focused on inflammatory responses after the occurrence of an intracerebral hemor-
rhage, and not before [43].
An interesting finding of our study is that the association between higher levels of granulo-
cytes and risk of ASCVD was more pronounced in younger individuals than older individuals
(age below the median [64 years]: adjusted HR [95% CI] for doubled granulocyte count = 2.32
[1.20–4.47], P< 0.001; age at or above the median: 1.67 [1.21–2.29], P = 0.002). Recently, an
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English study and a Dutch study found that while there has been a decline in mortality from
acute stroke within 30 days, stroke event rates have increased, and 15-year mortality risk in
young adults who have had a stroke remained elevated [44,45]. This suggests that stroke
awareness and stroke prevention need to start at much lower age to reduce the occurrence of
stroke in younger people. Our results show that inflammation reduction could be a potential
important strategy to achieve this.
Moreover, our study showed that coronary and intracranial carotid artery calcifications
substantially mediate the association of granulocytes with CHD and stroke, respectively. The
observed proportion of mediation for CHD was 19.0%, while for stroke the proportion mediated
was 14.9%. This is meaningful given the multiple mechanisms through which innate immunity
affects cardiovascular health, including atrial fibrillation (AF) and coagulation [46]. Indeed, the
infiltration of immune cells and proteins that cause an inflammatory response in cardiac tissue
and circulatory processes is associated with AF [47], and AF is in turn an important risk factor
for CHD and stroke. Another possible mediator is blood coagulation, since inflammation results
in activation of coagulation, due to tissue-factor-mediated thrombin generation, downregula-
tion of physiological anticoagulant mechanisms, and inhibition of fibrinolysis, increasing the
risk of CHD and stroke [48]. Furthermore, besides calcifications, plaques may consist of intra-
plaque hemorrhage and a lipid core. Although calcifications are an adequate quantitative mea-
sure for atherosclerosis, vulnerable plaques without calcification, which are more strongly
associated with ASCVD [49], are not quantified by this method. Therefore, it is plausible that
the true proportion of inflammation mediated through atherosclerosis of all plaque components
is actually higher than the measured proportion mediated through the calcification component.
Blood cell count measurements display short-term variability or measurement error, but
we do not expect that this variability affected our results for several reasons. First, we expect to
have captured a more chronic or stable effect of immune status because we used blood cell
counts measured at multiple time points per participant. Although this longitudinal informa-
tion was collected intermittently and with error, we could successfully reconstruct the com-
plete longitudinal history by postulating a suitable mixed effects model to describe participant-
specific time evolutions. The mixed model accounted for the measurement error problem by
postulating that the observed level of the blood cell count measurements equaled the true level
of the blood cell count measurements plus a random error term. Thus, the joint models we
used accounted for measurement error or variability of the blood cell count measurements.
Second, as a sensitivity analysis, we additionally excluded participants with a history of cancer
or a history of immune-modulating medication at baseline, and we performed additional
adjustments for NSAID use. We performed these sensitivity analyses specifically to address the
issue of participants having significantly altered blood cell counts due to underlying disease
processes. The results of these analyses did not show significant changes in our effect estimates.
Lastly, by extensively correcting for potential confounders such as BMI, we attempted to rule
out effects of determinants of blood cell counts as much as possible.
Our study has some limitations. First, studying the etiology of ASCVD, which is the focus
of this study, remains difficult within an epidemiological setting due to the limited availability
of surrogates for innate and especially adaptive immunity. Second, we could not directly relate
the effect of hs-CRP with the different blood cell measurements and ASCVD risk since we did
not have hs-CRP measurements available at study baseline, but only 1 round before. Third, the
vast majority of our population is of European ancestry (97.6%), potentially limiting generaliz-
ability to other ethnicities. Fourth, it is important to note the possible influence of unmeasured
confounders on our results. Fifth, due to the cross-sectional nature of the analyses regarding
the association between immunity markers and calcifications, there is potential for reverse
causality. However, according to the present evidence, it is very plausible that inflammation
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comes first since activation of endothelial cells results in increased expression of leukocyte
adhesion molecules and the release of chemokines, which attract leukocytes that subsequently
infiltrate the vascular wall and drive atherogenesis [50]. Finally, the measurement error for
both subclinical ASCVD and immune cell subsets limits the mediation analysis in its reliabil-
ity. However, since this measurement error introduces random error into the direct effect, it is
expected to lead to underestimation of the mediation. Of course, we cannot rule out that it
could bias the results in the opposite direction and inflate mediation estimates.
In conclusion, our study shows that increased granulocyte count, GLR, and SII are associ-
ated with a higher risk of ASCVD, whereas increased lymphocyte count is protective for
ASCVD in the general population. Moreover, higher levels of granulocytes are associated with
subclinical atherosclerosis, as measured by arterial calcifications. These calcifications explain a
substantial proportion of the link between granulocytes and ASCVD. Our findings support the
hypothesis that ASCVD results from an imbalance between innate and adaptive immunity.
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